A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis
Conditions
Bronchiectasis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Royal Papworth Hospital NHS Foundation Trust, Cambridge Centre for Lung Infection, Cambridge, United Kingdom
Contact: Principal Investigator (Charles Haworth)Tayside Medical Science Centre, Ninewells Hospital & Medical School, Dundee, United Kingdom
Contact: Principal Investigator (James D. Chalmers)NHS Lothian, Edinburgh, United Kingdom
Contact: Principal Investigator (Adam Hill)Glasgow Royal Infirmary, Glasgow, United Kingdom
Contact: Principal Investigator (Lyn Corry)The Leeds Teaching Hospitals NHS Trust, Saint James's University Hospital, Leeds, United Kingdom
Royal Bromptom Hospital (NHS Guy's and Thomas'), London, United Kingdom
Contact: Principal Investigator (Michael Loebinger)Manchester University NHS Foundation Trust, Manchester, United Kingdom
Contact: Principal Investigator (Robert Lord)Medicines Evaluation Unit (MEU), Manchester, United Kingdom
Contact: Principal Investigator (Dave Singh)University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Contact: Principal Investigator (Mary Carroll)
Study leads
James D. Chalmers
Principal Investigator
School of Medicine, University of Dundee, UK